<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329118</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3824-111</org_study_id>
    <nct_id>NCT03329118</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Between Simvastatin and SHR3824</brief_title>
  <official_title>Drug Interaction Study of Henagliflozin and Simvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of thr study is to investigate the potential interation between multiple oral
      doses of SHR3824 and single oral dose of Simvastatin in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 24, 2017</start_date>
  <completion_date type="Anticipated">December 8, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of SHR3824</measure>
    <time_frame>At protocol-specified times up to Day 7 and Day 8</time_frame>
    <description>Cmax (a measure of the body's exposure to SHR3824) will be compared before and after coadministration with Simvastatin .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of SHR3824</measure>
    <time_frame>At protocol-specified times up to Day 7 and Day 8</time_frame>
    <description>AUC(a measure of the body's exposure to SHR3824) will be compared before and after coadministration with Simvastatin .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) of Simvastatin and simavastatin acid .</measure>
    <time_frame>At protocol-specified times up to Day 1 and Day 8</time_frame>
    <description>AUC(a measure of the body's exposure to simvastatin and simavastatin acid) will be compared before and after coadministration with SHR3824 .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of simvastatin and simavastatin acid.</measure>
    <time_frame>At protocol-specified times up to Day 1 and Day 8</time_frame>
    <description>Cmax (a measure of the body's exposure to simvastatin and simavastatin acid) will be compared before and after coadministration with Simvastatin .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>up to day 15</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>SHR3824 1Omg,Simavastatin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3824, Simvastatin</intervention_name>
    <description>two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.</description>
    <arm_group_label>SHR3824 1Omg,Simavastatin 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers with a body mass index (BMI, a measure of a person's weight in
             relation to height) between 19 and 26 kg/m2

        Exclusion Criteria:

          -  History of hypoglycemia

          -  History of urinary tract infections,or genital infections

          -  History of current clinically significant medical illness as determined by the
             Investigator

          -  Known allergy to SHR3824 or Simvastatin or any of the excipients of the formulation of
             SHR3824 or Simvastatin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haiyan Liu, PhD</last_name>
    <phone>+86-15705155025</phone>
    <email>liuhaiyan@shhrp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Chen, Master</last_name>
    <phone>+86-13588084969</phone>
    <email>zrygcp@126.com</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR3824,simvastatin, drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

